#biopharmaceuticals

[ follow ]

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

PharmAbcine is advancing monoclonal antibody therapy, significantly targeting diseases with high efficacy and low side effects.

New generation of radioactive drugs strike cancer with molecular precision

X-ray therapy initiated a revolution in cancer treatment that has evolved significantly over the years, leading to more precise and effective therapies.
#funding

PhoreMost $12M Series B Financing to Advance Next-Gen Degrader Programs

PhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.
The company aims to move cancer treatment programs into preclinical development with this new funding.

In other news this week: VividQ secures 6.7M, Reliant AI bags 10.1M, in.hub raises funding, Agtech Startup of the Year, and more - Silicon Canals

VividQ raises funds to enhance immersive AR technology for various sectors.
Vandria secures funding to develop treatments for age-related neurological diseases.

PhoreMost $12M Series B Financing to Advance Next-Gen Degrader Programs

PhoreMost has raised $12 million in Series B funding, advancing its pipeline for oncology and inflammatory diseases.
The company aims to move cancer treatment programs into preclinical development with this new funding.

In other news this week: VividQ secures 6.7M, Reliant AI bags 10.1M, in.hub raises funding, Agtech Startup of the Year, and more - Silicon Canals

VividQ raises funds to enhance immersive AR technology for various sectors.
Vandria secures funding to develop treatments for age-related neurological diseases.
morefunding

A Healthy Patent Family Is A Tree That Continues to Bear Fruit

False policy narratives against patents hinder innovation progress, as multiple patents are essential for complex products like biopharmaceuticals.
[ Load more ]